Medtronic Announces Early Site Release of New Radial Artery Access Portfolio Following First-in-Patient Procedure

Acquisition of RIST Neurovascular Enhances Medtronic's Capabilities to Serve Patients Treated for Brain Aneurysms and Other Neurovascular Conditions

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced expansion of its limited site release of the recently acquired radial artery access portfolio from privately-held RIST Neurovascular, Inc., which includes the Rist™ 079 Radial Access Guide Catheter and Rist™ Radial Access Selective Catheter. Terms of the acquisition were not disclosed.

"Rist 079 Radial Access Guide Catheter is the first catheter that has been specifically designed for neurointerventions using the radial artery pathway in the wrist. This is the first-of-its-kind device that optimizes transition zones for the required navigability and support that is unique to the radial trajectory when compared to the femoral approach," said R. Webster Crowley , M.D., chief of Cerebrovascular and Endovascular Neurosurgery, Rush University Medical Center, who performed the first-in-patient procedure in September 2020 . "The Rist Radial Access portfolio gives clinicians who perform neurovascular procedures the full spectrum of access and delivery devices that are optimized for the patient's condition and anatomy. This should help improve the care we deliver to patients treated for neurovascular conditions."

The addition of the Rist 079 Radial Access Guide Catheter and Selective Catheter to the Medtronic neurovascular portfolio enhances the company's ability to serve patients that require interventional neurovascular therapy. Rist 079 Radial Access Guide Catheter and Rist Radial Access Selective Catheter received U.S. Food and Drug Administration (FDA) 501(k) clearance last year. 1

"The Rist radial access portfolio is an ideal strategic fit for Medtronic as our goal is to offer the most advanced, patient-preferred delivery tools to meet the needs of neurovascular professionals," said Stacey Pugh , president of the Neurovascular Therapies business, which is reported as part of the Restorative Therapies Group at Medtronic. "We are excited to announce that we have completed more than 80 cases in our limited market release evaluation at 12 institutions 2 and are very pleased with performance and physician feedback. We also will be developing and expanding the portfolio to fully serve the broad patient population."

Since 2018, the American Heart Association 3 has recommended transradial techniques for cardiovascular endovascular interventions for acute coronary syndrome citing lower bleeding and vascular complications than transfemoral artery access. The neuro-interventionalist community is examining adoption of the transradial approach to their practice.

The acquisition of RIST Neurovascular, Inc., closed in August 2020 and is the eighth in a series of tuck-in acquisitions Medtronic has announced since January 2020 . The revenue and earnings contribution is expected to be immaterial to the Medtronic Neurovascular business in the first two years and accretive thereafter. In addition, this transaction is expected to meet Medtronic's long-term financial metrics for acquisitions.

About the Rist Radial Access Catheters
The Rist 079 Radial Access Guide Catheter is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.

The Rist Radial Access Selective Catheter is indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature. It can be used to facilitate introduction of diagnostic agents in the neuro vasculature. It is not intended to facilitate introduction of diagnostic agents in coronary or peripheral arteries.

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

  1. Rist Neurovascular Inc. 510 K  K191551 and K201682
  2. Data on file
  3. https://www.ahajournals.org/doi/full/10.1161/HCV.0000000000000035

Contacts:


David T. Young

Ryan Weispfenning

Public Relations

Investor Relations

+1-774-284-2746

+1-763-505-4626

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-announces-early-site-release-of-new-radial-artery-access-portfolio-following-first-in-patient-procedure-301218657.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×